Non-dystrophic myotonia Chilean cohort with predominance of the SCN4A Gly1306Glu variant
Author
dc.contributor.author
Ávila Smirnow, Daniela
Author
dc.contributor.author
Vargas Leal, Carmen
Author
dc.contributor.author
Beytía Reyes, María de los Ángeles
Author
dc.contributor.author
Cortés Zepeda, Rocío
Author
dc.contributor.author
Escobar, Raúl G.
Author
dc.contributor.author
Kleinsteuber Saa, Karin
Author
dc.contributor.author
Lagos Lucero, Marcela
Author
dc.contributor.author
Avaria Benapres, María de los Ángeles
Author
dc.contributor.author
Padilla Pérez, Oslando
Author
dc.contributor.author
Casar Leturia, Juan Carlos
Author
dc.contributor.author
Mellado Sagredo, Cecilia
Author
dc.contributor.author
Sternberg, Damien
Admission date
dc.date.accessioned
2020-10-29T18:56:05Z
Available date
dc.date.available
2020-10-29T18:56:05Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Neuromuscular Disorders 30 (2020) 554–561
es_ES
Identifier
dc.identifier.other
10.1016/j.nmd.2020.04.006
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/177480
Abstract
dc.description.abstract
Non-dystrophic myotonias are a group of rare neuromuscular diseases linked to SCN4A or CLCN1 . Among the subtypes, myotonia
permanens, associated with the Gly1306Glu variant of SCN4A , is a relatively less frequent but more severe form. Most reports of nondystrophic
myotonias describe European populations. Therefore, to expand the genetic and phenotypic spectrum of this disorder, we evaluated
30 Chilean patients with non-dystrophic myotonias for associated variants and clinical characteristics. SCN4A variants were observed in 28
(93%) of patients, including 25 (83%) with myotonia permanens due to the Gly1306Glu variant. Myotonia permanens was inherited in 24
(96%) patients; the mean age of onset was 6 months, and the initial symptoms were orbicularis oculi myotonia in 17 (74%) patients and
larynx myotonia in 12 (52%) patients. The extraocular muscles were involved in 11 (44%) patients, upper limbs in 20 (80%), and lower
limbs in 21 (84%). Thirteen (52%) patients experienced recurrent pain and 10 (40%) patients reported limitations in daily life activities.
Carbamazepine reduced myotonia in eight treated patients. The high frequency of the Gly1306Glu variant in SCN4A in Chilean patients
suggests a founder effect and expands its phenotypic spectrum.